FHC
TVTX icon

First Horizon Corporation’s Travere Therapeutics TVTX Stock Holding History

First Horizon Corporation’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$123K Sell
2,161
-781
-27% -$34.6K ﹤0.01% 496
2026
Q1 		$87.4K Sell
2,942
-294
-9% -$8.79K ﹤0.01% 520
2025
Q4 		$124K Buy
3,236
+1,710
+112% +$55.6K 0.01% 481
2025
Q3 		$36.5K Buy
+1,526
New +$28.7K ﹤0.01% 685

Other funds holding TVTX

SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

First Horizon Corporation's TVTX Position: Q2 2026 in Review

First Horizon Corporation reduced its Travere Therapeutics (TVTX) stake by 27% in Q2 2026, selling an estimated $34.6K and leaving 2,161 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #496.

First Horizon Corporation first reported a position in TVTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $124K in Q4 2025. 62 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • First Horizon Corporation held 2,161 shares of Travere Therapeutics worth $123K as of Q2 2026.
  • First Horizon Corporation sold 781 Travere Therapeutics shares in Q2 2026, an estimated $34.6K.
  • Travere Therapeutics made up ﹤0.01% of First Horizon Corporation's portfolio in Q2 2026, its #496 holding.
  • First Horizon Corporation first reported a position in Travere Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • First Horizon Corporation's Travere Therapeutics position peaked at $124K in Q4 2025.
  • 62 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on First Horizon Corporation's 13F filing for Q2 2026, filed 20 Jul 2026.